Dark

Check out our Level2View

AGTC
Applied Genetic Technologies Corporation
stock NASDAQ

Inactive

Nov 30, 2022

0.3936USD+1.235%(+0.0048)764,531

Pre-market

0.00USD-100.000%(-0.39)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 11, 2022

08:06AM EST AGTC Exceeds Enrollment Target In SKYLINE Trial Of AGTC-501 For Treatment Of X-linked Retinitis Pigmentosa (XLRP) Benzinga

08:00AM EST -- Company on track to report three-month interim study results, including visual acuity, visual sensitivity, mobility and safety data, in Q2 2022 -- Company providing further updated guidance on other milestones GlobeNewswire Inc

Jan 4, 2022

08:00AM EST AGTC to Participate in the H.C. Wainwright BioConnect 2022 Conference GlobeNewswire Inc

Dec 6, 2021

08:00AM EST AGTC Appoints Biopharmaceutical Industry Leader James Robinson to GlobeNewswire Inc

Nov 16, 2021

08:00AM EST -- With 25+ years of experience, Dr. Scaria has led numerous gene therapy programs from early research into clinical development -- Dr. Scaria completes a newly expanded management team in place to continue development of late-stage programs in XLRP and Achromatopsia and advance AGTCs preclinical pipeline GlobeNewswire Inc

Nov 12, 2021

08:00AM EST AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at GlobeNewswire Inc

Nov 11, 2021

08:00AM EST -- Ms. DOyley-Gay brings significant legal experience as well as business development and commercial operations expertise from both biotech and pharmaceutical companies GlobeNewswire Inc

Nov 10, 2021

08:00AM EST AGTC to Participate in the Stifel 2021 Virtual Healthcare Conference GlobeNewswire Inc

Nov 9, 2021

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:32AM EST Applied Genetic Tech Q1 EPS $(0.40) Misses $(0.35) Estimate Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

07:00AM EST -Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022- GlobeNewswire Inc

Nov 2, 2021

08:00AM EDT AGTC to Host First Quarter Financial Results Conference Call and GlobeNewswire Inc

Oct 19, 2021

08:25AM EDT AGTC to Present At Upcoming Dry AMD Therapeutic Development Summit Benzinga

Oct 14, 2021

05:00PM EDT AGTC Announces Two Key Leadership Team Appointments GlobeNewswire Inc

Oct 12, 2021

11:09AM EDT AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa GlobeNewswire Inc

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

08:00AM EDT AGTC to Present at Upcoming Cell & Gene Management Meeting on the Mesa GlobeNewswire Inc

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Oct 1, 2021

07:56AM EDT The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 29, 2021

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

Sep 28, 2021

08:24AM EDT AGTC Clinical Trial Investigators To Present Data From Ongoing XLRP And Achromatopsia Phase 1/2 Trials At Fourteenth International Symposium On Retinal Degeneration Sept. 29 Benzinga

08:00AM EDT AGTC Clinical Trial Investigators to Present Data from Ongoing GlobeNewswire Inc

Sep 27, 2021

08:15AM EDT AGTC To Present At 2021 Cantor Fitzgerald Virtual Global Healthcare Conference Sept. 30 Benzinga

08:00AM EDT AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global GlobeNewswire Inc

07:51AM EDT Applied Genetic: Q4 Earnings Insights Benzinga

Sep 23, 2021

04:10PM EDT Applied Genetic Tech Q4 EPS $(0.28) Beats $(0.40) Estimate, Sales $500.00K Benzinga

04:05PM EDT -Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022- GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For September 23, 2021 Benzinga

Sep 19, 2021

09:46AM EDT The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions and Conference Presentations In The Spotlight Benzinga

Sep 16, 2021

08:00AM EDT AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial GlobeNewswire Inc

Sep 9, 2021

08:00AM EDT AGTC to Participate in Clinical Trials in Rare Diseases Conference GlobeNewswire Inc

Sep 8, 2021

08:00AM EDT Applied Genetic Technologies Corporation(Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced Jonathan I. Lieber as their new Chief Financial Officer. GlobeNewswire Inc

Sep 7, 2021

10:23AM EDT Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th, 2021. GlobeNewswire Inc

Aug 24, 2021

08:00AM EDT Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate GlobeNewswire Inc

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 19, 2021

04:05PM EDT -Program helps those living with Achromatopsia receive filtered glasses and contact lenses to qualify for bioptic driving- GlobeNewswire Inc

Aug 18, 2021

08:00AM EDT Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced the addition of Yehia Hashad, MD to its Board of Directors. GlobeNewswire Inc

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 16, 2021

08:00AM EDT -AGTC patient advocacy executive director will address genetic testing and gene therapy for the treatment of rare retinal diseases- GlobeNewswire Inc

Aug 2, 2021

04:05PM EDT Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that management will be participating in the following virtual investor conferences: GlobeNewswire Inc

Jul 23, 2021

10:44AM EDT UPDATE: Roth On Applied Genetic Technologies: Firm Sees Positive Expectations On 3 Month Data From SKYLINE Study During Q4; Highlights Advancements In Preclinical Programs Across Ophthalmology, Neuroscience, & Otology With Extensive Optimization Studies Benzinga

10:43AM EDT Roth Capital Maintains Buy Rating On Applied Genetic Technologies With $35 Price Target Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 8, 2021

07:02AM EDT Widely Recognized Experts and AGTC Leadership Will Expand on Recent ACHM Phase 1/2 Clinical Trial Data and Discuss XLRP Milestones GlobeNewswire Inc

Jun 28, 2021

10:29AM EDT UPDATE: Roth Capital On Applied Genetic Technologies Buy Rating: Firm Highlights Release Of Phase 1/2 Data For AGTC-401/402 As 'Limited Improvements' Seen In Adult CNGA3-Patients But 'Encouraging Improvements' In Adult CNGB3-Patients. Benzinga

10:28AM EDT Roth Capital Maintains Buy Rating On Applied Genetic Technologies, Price Target $35. Benzinga

Jun 24, 2021

08:12AM EDT The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO Benzinga

07:12AM EDT AGTC Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene Benzinga

07:00AM EDT - Activities to support the next stage of clinical development of ACHM B3 candidate are ongoing- GlobeNewswire Inc

04:56AM EDT The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 4.55 A.M.) RTTNews

Jun 23, 2021

04:03PM EDT AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss GlobeNewswire Inc

Jun 22, 2021

07:00AM EDT -AGTC patient advocacy executive director will highlight the state of gene therapytrial recruitment for IRDs- GlobeNewswire Inc

Jun 15, 2021

10:24AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 Benzinga

06:47AM EDT BTIG Initiates Coverage On Applied Genetic with Buy Rating, Announces Price Target of $11 Benzinga

May 26, 2021

07:00AM EDT AGTC Appoints Regulatory Expert, Janet C. Rae, RAC, as SVP of Global Regulatory and Quality GlobeNewswire Inc

May 17, 2021

04:18PM EDT Applied Genetic Tech Q3 EPS $(0.40) Beats $(0.41) Estimate Benzinga

04:05PM EDT - Reported 50% response rate in visual sensitivity among patients in highest dose groups in ongoing Phase 1/2 clinical trial of its XLRP gene therapy candidate for patients who met inclusion criteria for Skyline and Vista trials - GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For May 17, 2021 Benzinga

May 14, 2021

02:59PM EDT Otonomy's OTO-825 Gene Therapy Can Restore Meaningful Hearing Function, Animal Study Shows Benzinga

12:55PM EDT Concept Companies Breaks Ground on Expansion for AGTC in Alachua's Foundation PR Newswire

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

07:30AM EDT Otonomy and AGTC Present Preclinical Proof-of-Concept Results GlobeNewswire Inc

May 13, 2021

04:03PM EDT - Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - GlobeNewswire Inc

May 11, 2021

04:05PM EDT AGTC to Host Third Quarter Financial Results Conference Call and GlobeNewswire Inc

07:00AM EDT -Improved process and validated expression assay support clinical phase product release for the Vista Phase 2/3 XLRP clinical trial- GlobeNewswire Inc

May 6, 2021

09:04AM EDT Applied Genetic's XLRP Gene Therapy Shows Improved, Durable Response In Retinal Sensitivity Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

07:26AM EDT AGTC Reports 12-Month Data From Highest Dose Groups In Ongoing XLRP Phase 1/2 Clinical Trial; Groups 5 And 6 Had 50% Response Rate Among Patients Who Met Inclusion Criteria Benzinga

07:00AM EDT -Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials- GlobeNewswire Inc

May 5, 2021

04:05PM EDT AGTC to Host Conference Call on May 6 at 8:00 AM ET to Discuss GlobeNewswire Inc

May 4, 2021

08:00AM EDT AGTC Advances in AAV Gene Therapy Manufacturing to be Presented at GlobeNewswire Inc

May 3, 2021

08:42AM EDT AGTC Clinical Investigators To Present Data From Ongoing XLRP And Achromatopsia Phase 1/2 Trials At Benzinga

08:40AM EDT -Company remains on track to present additional 12-month data from the XLRP and achromatopsia clinical trials in the second quarter of 2021- GlobeNewswire Inc

Apr 29, 2021

07:37AM EDT Applied Genetic Technologies Corporation To Present Data At Association For Research In Vision And Ophthalmology 2021 Virtual Annual Meeting Mat 3 And May 6 Benzinga

07:30AM EDT AGTC Announces Data to be Presented from the Ongoing XLRP and GlobeNewswire Inc

Apr 28, 2021

08:00AM EDT Otonomy, AGTC To Present Preclinical Proof-Of-Concept Results For OTO-825 Gene Therapy At ASGCT Annual Meeting Benzinga

07:30AM EDT Otonomy and AGTC to Present Preclinical Proof-of-Concept Results GlobeNewswire Inc

Apr 27, 2021

07:41AM EDT The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout Benzinga

Apr 26, 2021

04:02PM EDT AGTC Announces Departure of Chief Scientific Officer GlobeNewswire Inc

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 19, 2021

07:00AM EDT -Technology To Be Incorporated In MultipleSparingVision SAS Programs- GlobeNewswire Inc

Apr 13, 2021

07:15AM EDT TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program Benzinga

07:00AM EDT - AGTC Transfers Clinical Trial Materials and Phase 1/2 Data To TeamedON - GlobeNewswire Inc

Mar 31, 2021

08:00AM EDT Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Company management will participate in the following virtual conferences: GlobeNewswire Inc

Mar 25, 2021

07:00AM EDT -AGTCs deep commitment to the patient voice drives solutions to support patient access to information and to improve the experience of patients participating in clinical trials- GlobeNewswire Inc

Mar 18, 2021

12:00PM EDT -AGTC will highlight the value of the patient voice in gene therapy development- GlobeNewswire Inc

Mar 2, 2021

01:12PM EST Stifel Initiates Coverage On Applied Genetic with Buy Rating, Announces Price Target of $14 Benzinga

07:00AM EST Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in the following virtual investor conferences: GlobeNewswire Inc

Feb 18, 2021

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

Feb 17, 2021

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

Feb 16, 2021

12:00PM EST AGTC to Present at the OIS Gene Therapy Innovation Showcase on GlobeNewswire Inc

08:00AM EST -AGTC executives will address critical success factors in gene therapy manufacturing and the value of the patient perspective in gene therapy development --- GlobeNewswire Inc

Feb 11, 2021

07:00AM EST - Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022 - GlobeNewswire Inc

03:51AM EST Earnings Scheduled For February 11, 2021 Benzinga

Feb 6, 2021

12:42PM EST The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight Benzinga

Feb 4, 2021

12:03PM EST Article reflects Companys leadership and innovation in scalable, reproducible manufacture of adeno-associated virus (AAV)-based gene therapies GlobeNewswire Inc

07:00AM EST AGTC to Host Second Quarter Financial Results Conference Call and GlobeNewswire Inc

Feb 1, 2021

12:14PM EST Roth Capital Maintains Buy on Applied Genetic, Raises Price Target to $35 Benzinga

Jan 28, 2021

08:22AM EST Applied Genetic Technologies Corporation Prices Offering Of 16,741,573 Shares Of Common Stock And Warrants To Purchase 8,370,786 Shares At $4.45/Unit Benzinga

08:08AM EST AGTC Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire Inc

08:03AM EST The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO Benzinga

Jan 27, 2021

04:36PM EST AFTC Announces A Common Stock Offering; No Terms Disclosed Benzinga

04:36PM EST AGTC Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire Inc

04:25PM EST AGTC Announces First Reported Improvements in Visual Sensitivity for Achromatopsia (ACHM) patients from its Ongoing Clinical Trials Benzinga

04:19PM EST -Preliminary results suggest sustained improvements to 12-months in visual sensitivity, as measured by full field static perimetry, supported in some patients by other endpoints--Company plans longer term follow-up, dosing of younger pediatric patients, and addition of new brain imaging and color brightness tests- GlobeNewswire Inc

Jan 6, 2021

04:01PM EST AGTC to Participate in the H.C. Wainwright BioConnect 2021 Conference GlobeNewswire Inc

Nov 17, 2020

10:49AM EST Roth Capital Maintains Buy on Applied Genetic, Raises Price Target to $30 Benzinga

10:42AM EST UPDATE: Roth Raises Target On Applied Genetics Technologies, Says 'Despite the market not fully appreciating the data given how the stock traded, we continue to believe that the results suggest that AGTC could have a best-in-class therapy' Benzinga

Nov 16, 2020

04:25PM EST Applied Genetic Tech Q1 EPS $(0.60) Up From $(0.64) YoY Benzinga

04:05PM EST AGTC Announces Financial Results and Business Update for the GlobeNewswire Inc

Nov 11, 2020

10:57AM EST Berenberg Initiates Coverage On Applied Genetic with Buy Rating, Announces Price Target of $15 Benzinga

07:38AM EST The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga

07:08AM EST AGTC Reports Additional Data From Phase 1/2 Clinical Trial In Patients With X-Linked Retinitis Pigmentosa Benzinga

07:00AM EST - Durable improvements observedin visual sensitivity and visual acuity over a wide dose-range with a favorable safety profile - GlobeNewswire Inc

Nov 10, 2020

04:05PM EST AGTC to Host Conference Call on November 11 at 8:00 am ET to GlobeNewswire Inc

Oct 21, 2020

07:00AM EDT AGTC to Participate in Cantor Fitzgerald Virtual Panel: Key GlobeNewswire Inc

Oct 8, 2020

07:00AM EDT Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that management will participate in the following virtual conferences: GlobeNewswire Inc

Oct 7, 2020

07:00AM EDT AGTC Joins the My Retina Tracker Program as a New GlobeNewswire Inc

Sep 9, 2020

02:30PM EDT Mid-Afternoon Market Update: Nasdaq Surges 300 Points; Slack Shares Plunge Benzinga

12:05PM EDT Mid-Day Market Update: Dow Jumps Over 500 Points; Trillium Therapeutics Shares Spike Higher Benzinga

07:35AM EDT Applied Genetic Tech Q4 EPS $(0.56) Misses $(0.48) Estimate Benzinga

07:00AM EDT - Planned Phase 2/3 trial expected to include approximately 60 patients and a responder analysis based on at least 7 decibel improvement in visual sensitivity in at least 5 loci across two active dose groups and one control group - GlobeNewswire Inc

04:01AM EDT Earnings Scheduled For September 9, 2020 Benzinga

Sep 8, 2020

08:20AM EDT Benzinga Pro's Stocks To Watch For Tues., Sept. 8, 2020: GM, LULU, XHB, AGTC, GNRC Benzinga

Sep 3, 2020

04:05PM EDT Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that management will be participating in the following virtual conferences: GlobeNewswire Inc

Sep 2, 2020

05:36PM EDT After Hours Market: PVH, Fulgent Genetics, Applied Genetic RTTNews

04:05PM EDT AGTC to Host Management Update on September 9 at 8:00 am ET to GlobeNewswire Inc

Aug 25, 2020

07:10AM EDT AGTC Announces Publication Of Preclinical Data That 'Support The Ongoing Clinical Development Of Its XLRP Gene Therapy Program' Benzinga

07:00AM EDT AGTC Announces Publication of Preclinical Data that Support the GlobeNewswire Inc

Aug 12, 2020

07:00AM EDT Patient Advisory Council to include advocates from the inherited retinal diseases global community GlobeNewswire Inc

Aug 4, 2020

07:00AM EDT AGTC to Present at the Wedbush PacGrow Virtual Healthcare GlobeNewswire Inc

Jul 22, 2020

07:07AM EDT AGTC Announces Updated Development Plan For Its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start Of Planned Phase 2/3 Trial Benzinga

07:00AM EDT AGTC Announces Updated Development Plan for its X-Linked Retinitis GlobeNewswire Inc

Share